
Herantis to advance Alzheimer’s treatment after FDA meeting
Herantis is set to advance the clinical development of its Alzheimer’s therapy following a positive meeting with the US Food and Drug Administration (FDA). The company reports it completed a pre-IND meeting with the FDA to discuss the planned clinical development of HER-096, a first-in-class small peptide being developed to treat Alzheimer’s disease. … Read More

